Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics reported positive Phase 1/2 data for vopimetostat combined with daraxonrasib, achieving a 92% objective response rate in MTAP-deleted, RAS-mutant pancreatic cancer. The company plans to advance the combination into Phase 3 development and will present the full dataset at the ESMO Congress in October. Financially, the company reported a net loss of $55.3 million, or $0.37 per share, for the quarter, compared to a loss of $38.9 million in the prior year. Despite the widening losses, Tango maintains a strong cash position of $1.0 billion, which it expects to fund its current operating plan through late-stage development.
Key figures
- Revenue
- 0
- Orr
- 92%
- Net loss
- $55.3 million
- Pfs rate
- 90%
- Rd expenses
- $37.2 million
- Cash position
- $1.0 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.